Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Multimodality Therapy Including Pleurectomy/Decortication in Pleural Mesothelioma: Long-Term Outcomes in 152 Consecutive Patients A Retrospective Cohort Study

March 6, 2025 By Law Offices of Thomas J. Lamb, P.A.

Objective:  Evaluate the long-term outcomes of pleurectomy decortication, systemic chemotherapy and prophylactic radiotherapy in pleural mesothelioma (PM). Summary background data:  There is no known cure for PM and cytoreductive surgery remains controversial. Methods:  Retrospective analysis of a cohort of patients treated consecutively … [Read more...]

Filed Under: Mesothelioma Tagged With: chemotherapy, decortication, mesothelioma treatments, pleural mesothelioma, pleurectomy, radiotherapy

Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities

February 20, 2025 By Law Offices of Thomas J. Lamb, P.A.

Mesothelioma is a malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. Due to the prolonged time needed for one to fully develop mesothelioma, difficulty in diagnosing this condition early, its quick progression once manifested, and the limited treatment options, the prognosis for this condition … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

Treatment of Pleural Mesothelioma: ASCO Guideline Update

February 3, 2025 By Law Offices of Thomas J. Lamb, P.A.

Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018 considerable progress has been made which has changed not only the management but even the name of this disease. This guideline update focuses on four key areas: the role of … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

November 21, 2024 By Law Offices of Thomas J. Lamb, P.A.

Introduction The purpose of this guideline is to provide recommendations for the management of patients with malignant pleural mesothelioma (MPM), an aggressive tumor with a poor prognosis. In the United States, about 3,000 new cases are diagnosed each year. The median overall survival of patients with advanced surgically unresectable disease is … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies

October 11, 2024 By Law Offices of Thomas J. Lamb, P.A.

Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune … [Read more...]

Filed Under: Mesothelioma Tagged With: immunotherapy, mesothelioma treatments, pleural mesothelioma

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

September 19, 2024 By Law Offices of Thomas J. Lamb, P.A.

The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda (pembrolizumab) ] plus chemotherapy (n = 222) significantly … [Read more...]

Filed Under: Mesothelioma Tagged With: Keytruda, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment

September 6, 2024 By Law Offices of Thomas J. Lamb, P.A.

Abstract:  The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the nucleotide salvage pathway and is involved in the adaptive stress response to chemotherapy. The … [Read more...]

Filed Under: Asbestos Tagged With: chemotherapy, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

July 26, 2024 By Law Offices of Thomas J. Lamb, P.A.

Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

July 18, 2024 By Law Offices of Thomas J. Lamb, P.A.

Background:  Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. Methods:  MARS 2 was a phase 3, national, multicentre, … [Read more...]

Filed Under: Mesothelioma Tagged With: chemotherapy, decortication, mesothelioma, mesothelioma treatments, pleural mesothelioma, pleurectomy

Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma

April 17, 2024 By Law Offices of Thomas J. Lamb, P.A.

Asbestos exposure is known as the main elicitor of pleural mesothelioma (PM) development. The pathology’s rarity, wide range of growth patterns, and devastating prognosis have hindered a standardized treatment to date. This study intended to determine possible prognosticators contributing to adjusting the treatment allocation. This initiated the … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

  • 1
  • 2
  • 3
  • 4
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.